STERIS plc (NYSE:STE) Receives $241.60 Average Target Price from Analysts

Shares of STERIS plc (NYSE:STE) have earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $241.60.

Several brokerages recently issued reports on STE. JMP Securities reissued a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research note on Thursday, May 9th. Piper Sandler reissued a “neutral” rating and issued a $225.00 price objective (up from $220.00) on shares of STERIS in a research note on Friday, May 10th. StockNews.com raised STERIS from a “hold” rating to a “buy” rating in a research note on Saturday, June 15th. Finally, Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research note on Friday, May 10th.

Insider Activity

In other news, Director Jacqueline B. Kosecoff sold 4,584 shares of the stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $231.53, for a total transaction of $1,061,333.52. The sale was disclosed in a document filed with the SEC, which is available at this link. In other STERIS news, VP Renato Tamaro sold 1,154 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $231.64, for a total value of $267,312.56. Following the sale, the vice president now owns 6,677 shares of the company’s stock, valued at approximately $1,546,660.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jacqueline B. Kosecoff sold 4,584 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $231.53, for a total value of $1,061,333.52. The disclosure for this sale can be found here. In the last quarter, insiders have sold 7,762 shares of company stock valued at $1,798,477. Insiders own 1.14% of the company’s stock.

Institutional Trading of STERIS

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Personal Financial Services acquired a new stake in STERIS in the 1st quarter valued at approximately $25,000. J.Safra Asset Management Corp grew its holdings in shares of STERIS by 77.9% during the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 53 shares in the last quarter. Quent Capital LLC grew its holdings in shares of STERIS by 112.7% during the 1st quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 71 shares in the last quarter. VisionPoint Advisory Group LLC acquired a new stake in shares of STERIS during the 4th quarter worth approximately $34,000. Finally, Headlands Technologies LLC acquired a new stake in shares of STERIS during the 1st quarter worth approximately $36,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Trading Down 0.4 %

Shares of NYSE STE opened at $217.38 on Tuesday. STERIS has a 12 month low of $195.47 and a 12 month high of $254.00. The company has a market cap of $21.49 billion, a price-to-earnings ratio of 56.91 and a beta of 0.83. The company has a quick ratio of 2.36, a current ratio of 3.08 and a debt-to-equity ratio of 0.49. The business has a fifty day simple moving average of $221.30 and a 200-day simple moving average of $221.22.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, May 8th. The medical equipment provider reported $2.58 EPS for the quarter, beating the consensus estimate of $2.41 by $0.17. STERIS had a return on equity of 13.73% and a net margin of 6.95%. The business had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.41 billion. During the same period in the prior year, the business posted $2.30 earnings per share. STERIS’s revenue was up 10.8% compared to the same quarter last year. Sell-side analysts predict that STERIS will post 9.24 EPS for the current year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 26th. Stockholders of record on Wednesday, June 12th were issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date was Wednesday, June 12th. STERIS’s dividend payout ratio is 54.45%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.